Role of carboplatin in the treatment of lung cancer
Bréchot, J.M.
Bulletin du Cancer 87(Special Issue): 34-39
2000
ISSN/ISBN: 0007-4551
PMID: 11082721
Accession: 047283403
Carboplatin is a cytotoxic drug used in non-small cell and small cell lung cancer. Its role in advanced disease, but also in combination with radiotherapy, in neoadjuvant treatment and in the treatment approach in elderly patients is reviewed. New cytotoxic drug combinations are described.
PDF emailed within 1 workday: $29.90
Related References
Ettinger, D.S. 1998: The role of carboplatin in the treatment of small-cell lung cancer Oncology 12(1 Suppl 2: 36-43Shparyk, I. 1997: Cisplatin + carboplatin in the treatment of non-small cell lung cancer Role of dose intensity European Respiratory Journal Suppl 10(25): 197S
Bunn, P.A. 2002: The role of irinotecan combined with Cisplatin or Carboplatin in the treatment of advanced non-small-cell lung cancer Clinical Lung Cancer 4 Suppl. 1: S5-S9
Jiang, T.; Xiong, H.; Tang, X.; Liu, Z. 2003: A clinical study on efficacy of gemcitabine and carboplatin versus paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer Zhongguo Fei Ai Za Zhi 6(2): 135-137
Li, D.-x.; Chen, X.-b. 2002: Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer Ai Zheng 21(4): 412-415
Rodrigues-Pereira, J.é; Kim, J.-H.; Magallanes, M.; Lee, D.H.; Wang, J.; Ganju, V.; Martínez-Barrera, L.; Barraclough, H.; van Kooten, M.; Orlando, M. 2011: A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 6(11): 1907-1914
Schmittel, A.; Fischer von Weikersthal, L.; Sebastian, M.; Martus, P.; Schulze, K.; Hortig, P.; Reeb, M.; Thiel, E.; Keilholz, U. 2006: A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer Annals of Oncology: Official Journal of the European Society for Medical Oncology 17(4): 663-667
Eba, J.; Shimokawa, T.; Nakamura, K.; Shibata, T.; Misumi, Y.; Okamoto, H.; Yamamoto, N.; Ohe, Y. 2015: A Phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201) Japanese Journal of Clinical Oncology 45(1): 115-118
Socinski, M.A.; Raju, R.N.; Stinchcombe, T.; Kocs, D.M.; Couch, L.S.; Barrera, D.; Rousey, S.R.; Choksi, J.K.; Jotte, R.; Patt, D.A.; Periman, P.O.; Schlossberg, H.R.; Weissman, C.H.; Wang, Y.; Asmar, L.; Pritchard, S.; Bromund, J.; Peng, G.; Treat, J.; Obasaju, C.K. 2010: Randomized, phase Ii trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 5(12): 1963-1969
Klastersky, J. 1988: Cisplatin and carboplatin in combination with etoposide as a treatment for non-small cell lung cancer: the experience of the EORTC Lung Cancer Working Party Cancer Treatment Reviews 15 Suppl B: 33-40
Grønberg, B.ør.H.; Bremnes, R.M.; Fløtten, O.; Amundsen, T.; Brunsvig, P.F.; Hjelde, H.H.; Kaasa, S.; von Plessen, C.; Stornes, F.øy.; Tollåli, T.; Wammer, F.; Aasebø, U.; Sundstrøm, S. 2009: Phase IIi study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 27(19): 3217-3224
Pereira, J.é R.; Cheng, R.; Orlando, M.; Kim, J.-H.; Barraclough, H. 2013: Elderly subset analysis of randomized phase IIi study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer Drugs in R&d 13(4): 289-296
Ren, L.; Hou, M.; Yi, C.; Luo, D.; Qiu, M.; Xie, M.; Mei, Z. 1999: Comparison between carboplatin and cisplatin plus etoposide and carboplatin plus etoposide in the treatment of small cell lung cancer. Zhongguo Fei Ai Za Zhi 2(2): 87-89
Wang, H.-y.; Zhang, X.-r. 2014: Comparison of efficacy and safety between liposome-paclitaxel injection plus carboplatin and paclitaxel plus carboplatin as first line treatment in advanced non-small cell lung cancer Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae 36(3): 305-308
Helsing, M.; Thaning, L.; Sederholm, C.; Lamberg, K.; Martinsson, J.E.; Ek, L.; Månsson, T.; Andersson, L.; Hero, U.; Anjedani, D.; Svennson, G. 1999: Treatment with paclitaxel 1-h infusion and carboplatin of patients with advanced non-small-cell lung cancer: a phase Ii multicentre trial. Joint Lung Cancer Study Group Lung Cancer 24(2): 107-113